MedTrace Logo

Platelet Reactivity Inhibition Following Ticagrelor Loading Dose and One Year Outcome

NCT02428725 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 640

Last updated 2018-04-09

No results posted yet for this study

Summary

This study will try to determine if the measure of the platelet reactivity of the patients receiving from the ticagrelor continuation in an acute coronary syndrome handled by coronary angioplasty allows to predict the hemorrhagic risk.

Conditions

  • Acute Coronary Syndrome

Interventions

OTHER

blood sample

Biological samples will be done to determine platelet reactivity testing by VASP-index, will be obtained between 6 and 12 hours after receiving ticagrelor

Sponsors & Collaborators

  • Assistance Publique Hopitaux De Marseille

    lead OTHER

Principal Investigators

  • Laurent BONELLO, MD · Assistance Publique Hopitaux De Marseille

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2018-04-30
Completion
2018-04-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02428725 on ClinicalTrials.gov